Reported Saturday, Novartis' Latest Phase III Data For Fabhalta (iptacopan) In C3 glomerulopathy (C3G) A Significant 35.1% Reduction In Proteinuria Compared To Placebo
Portfolio Pulse from Benzinga Newsdesk
Novartis reported significant Phase III data for Fabhalta (iptacopan) in treating C3 glomerulopathy (C3G), showing a 35.1% reduction in proteinuria compared to placebo. The drug also showed numerical improvement in eGFR over 6 months and a favorable safety profile. C3G is a rare kidney disease with no current treatments, and Fabhalta targets its underlying cause.
May 28, 2024 | 7:51 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Novartis' Phase III data for Fabhalta in C3G shows a significant 35.1% reduction in proteinuria and numerical improvement in eGFR over 6 months. The drug has a favorable safety profile and targets the underlying cause of C3G, a rare kidney disease with no current treatments.
The positive Phase III results for Fabhalta in treating C3G, a rare and currently untreatable kidney disease, are likely to boost investor confidence in Novartis. The significant reduction in proteinuria and improvement in eGFR, along with a favorable safety profile, suggest strong potential for regulatory approval and market adoption.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100